High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
44.71B
+12.25%
2.052
-15.22%
44.88B
+6.8%
1.545
-4.61%
44.28B
+8.51%
0.745
-6.83%
Estimates Revision
The market is revising Upward the revenue expectations for Centene Corporation (CNC) for FY2025, with the revenue forecasts being adjusted by 4.61% over the past three months. During the same period, the stock price has changed by -7.31%.
Revenue Estimates for FY2025
Revise Upward
+4.61%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.16%
In Past 3 Month
Stock Price
Go Down
-7.31%
In Past 3 Month
12 Analyst Rating
0Wall Street analysts forecast CNC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNC is 73.60 USD with a low forecast of 61.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
5 Hold
0 Sell
Moderate Buy
0Current: 54.910
Low
61.00
Averages
73.60
High
90.00
0Current: 54.910
Low
61.00
Averages
73.60
High
90.00
Morgan Stanley
Overweight
initiated
$70
2025-06-09
Reason
Morgan Stanley
Price Target
$70
2025-06-09
initiated
Overweight
Reason
Morgan Stanley initiated coverage of Centene with an Overweight rating and $70 price target. While "varying permutations of policy headwinds are looming" across Medicaid, the overhang is disproportionately reflected in Centene at "trough valuations," the analyst tells investors in a research note. The firm sees a strengthening Medicaid footprint and dual eligible integration potential for the company. Policy risk is a key variable but could be more manageable than feared, contends Morgan Stanley. While the Medicaid sector is not without risk, the overhangs are largely reflected in valuations at 10-year troughs, on average, contends the firm.
Barclays
Overweight -> Equal Weight
downgrade
$84 -> $65
2025-06-02
Reason
Barclays
Price Target
$84 -> $65
2025-06-02
downgrade
Overweight -> Equal Weight
Reason
Barclays downgraded Centene to Equal Weight from Overweight with a price target of $65, down from $84. Following Q1 earnings and "several negative data points" around Part D mix, Affordable Care Act trend, and preliminary 2026 ACA rates, the firm is more concerned on the Medicare Part D and individual ACA businesses, which it believes carry negative earnings risk for the balance of 2025 and face significant premium increases and disruption in 2026. With limited prospects of multiple expansion and an unfavorable managed care catalyst calendar, investors are likely to be more sensitive to earnings revisions, which skew negatively for Part D- and ACA-sensitive stocks, such as Centene, the analyst tells investors in a research note.
Baird
Michael Ha
Hold
Maintains
$71 → $69
2025-04-15
Reason
Baird
Michael Ha
Price Target
$71 → $69
2025-04-15
Maintains
Hold
Reason
Guggenheim
Jason Cassorla
Hold
Initiates
n/a
2025-04-09
Reason
Guggenheim
Jason Cassorla
Price Target
n/a
2025-04-09
Initiates
Hold
Reason
Jefferies
David Windley
Sell
to
Hold
Upgrades
$53 → $64
2025-04-08
Reason
Jefferies
David Windley
Price Target
$53 → $64
2025-04-08
Upgrades
Sell
to
Hold
Reason
Jefferies upgraded Centene to Hold from Underperform with a price target of $64, up from $53. Jefferies expects near-term multiple reflation off historical lows given healthy Medicaid rate updates and retros in Q1 as per channel checks, and Republican lawmakers equivocating on deep budget cuts, the analyst tells investors in a research note. If retro rates land, core Medicaid rate updates are equal or better than management's guidance, and policy optics improve slightly, valuation could improve materially, as could 2025 EPS, the firm argues.
Wells Fargo
Stephen Baxter
Buy
Maintains
$76 → $72
2025-02-14
Reason
Wells Fargo
Stephen Baxter
Price Target
$76 → $72
2025-02-14
Maintains
Buy
Reason
Wells Fargo analyst Stephen Baxter lowered the firm's price target on Centene to $72 from $76 and keeps an Overweight rating on the shares. Q4 results were messy, with higher Medicaid MLR creating a more difficult jump-off point heading into 2025, the firm says. Earnings power recovery remains a significant opportunity but visibility to pacing and clarity on political backdrop will each take some time, adds Wells.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Centene Corp (CNC.N) is 7.36, compared to its 5-year average forward P/E of 11.80. For a more detailed relative valuation and DCF analysis to assess Centene Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Strongly Undervalued
5Y Average PE
11.80
Current PE
7.36
Overvalued PE
13.84
Undervalued PE
9.77
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Strongly Undervalued
5Y Average EV/EBITDA
9.18
Current EV/EBITDA
6.95
Overvalued EV/EBITDA
10.18
Undervalued EV/EBITDA
8.18
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Strongly Undervalued
5Y Average PS
0.28
Current PS
0.15
Overvalued PS
0.34
Undervalued PS
0.23
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 226.3% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
CNC News & Events
Events Timeline
(ET)
2025-06-16
16:31:35
Senate Republicans abandon Medicare cost cuts, Bloomberg reports
2025-06-05 (ET)
2025-06-05
14:06:21
Senate Republicans consider Medicare spending cuts, Bloomberg says
2025-06-04 (ET)
2025-06-04
06:10:27
Trump conceals Medicaid cuts in effort to pass major tax bill, Bloomberg says
Sign Up For More Events
Sign Up For More Events
News
Preview
4.0
06-13NASDAQ.COMCentene (CNC) Upgraded to Buy: What Does It Mean for the Stock?
Preview
6.0
06-10BenzingaMorgan Stanley Initiates Coverage On Centene with Overweight Rating, Announces Price Target of $70
Preview
8.0
06-04SeekingAlphaTrump’s tax bill projected to leave nearly 11M without insurance: CBO
Sign Up For More News
People Also Watch
FAQ
What is Centene Corp (CNC) stock price today?
What is Centene Corp (CNC)'s business?
What is the price predicton of CNC Stock?
What is Centene Corp (CNC)'s revenue for the last quarter?
What is Centene Corp (CNC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Centene Corp (CNC)'s fundamentals?
How many employees does Centene Corp (CNC). have?